Abstract

There have been inconsistent reports that Metrnl-like protein, a new adipokine, is associated with the risk of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). A systematic search in PubMed, Scopus, Web of Science, and Google scholar databases were conducted up until 24 November 2020. Ten eligible studies were included in this meta-analysis. The overall results showed that there was no significant association between serum Metrnl levels and risk of T2DM and CAD in patients compared with healthy control (SMD= −0.717 and 95%CI −1.572_0.139, p = .1). However, in subgroup analysis, there was a significant association between a BMI ≥ 25 and the serum level of Metrnl-like protein (SMD= −0.688 and 95%CI −1.348_−0.028 p = .041), indicating a potential inverse connection between serum Metrnl and the adiposity. Further well-designed studies are needed to explain the more subtle roles of Metrnl in metabolic disorders like T2DM and CAD.

摘要

关于 Metrnl 样蛋白（一种新的脂肪因子）与代谢综合征 (MetS)、2 型糖尿病 (T2DM) 和冠状动脉疾病 (CAD) 风险相关的报道不一致。截至 2020 年 11 月 24 日，我们在 PubMed、Scopus、Web of Science 和 Google 学者数据库中进行了系统检索。本次荟萃分析纳入了 10 项符合条件的研究。总体结果显示，与健康对照相比，患者血清Metrnl水平与T2DM和CAD风险之间没有显着相关性（SMD= -0.717和95%CI -1.572_0.139，p = .1 ） 。 然而，在亚组分析中，BMI ≥  25 与 Metrnl 样蛋白血清水平之间存在显着相关性（SMD= -0.688 和 95%CI -1.348_−0.028 p  =  .041），表明潜在的反向关系血清 Metrnl 和肥胖之间的关系。需要进一步精心设计的研究来解释 Metrnl 在 T2DM 和 CAD 等代谢性疾病中更微妙的作用。